CNQ · MVMD.CN
Mountain Valley MD Holdings Inc.
CA$0.07+CA$0.01 (+7.69%)
Mountain Valley MD Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
Loading market information…
TSX · APS.TO · CAD
Stock price, earnings
Quote as of Jul 3, 2026, 07:46 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Aptose Biosciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aptose Biosciences Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aptose Biosciences Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing personalized therapeutic solutions for challenging oncology cases, primarily within the United States. Its robust pipeline features several key clinical programs: APTO-253, currently in Phase 1a/b trials, targets patients with relapsed or refractory blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another candidate, HM43239, is undergoing Phase 1/2 evaluation for the treatment of relapsed or refractory AML. Aptose is also developing luxeptinib, which is in Phase 1a/b clinical studies for individuals battling relapsed or refractory B-cell malignancies, encompassing chronic lymphocytic leukemia, small lymphocytic lymphoma, various non-Hodgkin's lymphomas, as well as AML and HR MDS. Furthermore, the company is progressing with APL-581, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. Aptose maintains strategic alliances with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986 and headquartered in Toronto, Canada, the company was formerly known as Lorus Therapeutics Inc., changing its name to Aptose Biosciences Inc. in August 2014.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:10 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -CA$0.43+63.56% vs estimate |
| CA$0.00 |
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$0.07+CA$0.01 (+7.69%)
Mountain Valley MD Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
CA$0.04CA$0.00 (0.0%)
Kane Biotech Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.0% below the high.
CA$0.02-CA$0.01 (-25.0%)
Revive Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 81.25% below the high.
CA$0.05+CA$0.01 (+11.11%)
Avricore Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
CA$0.11+CA$0.01 (+10.0%)
Mercanto Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.29% below the high.
CA$0.05CA$0.00 (0.0%)
Telo Genomics Corp.’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
CA$0.07-CA$0.01 (-7.14%)
Restart Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 51.85% below the high.
$1.03-$0.02 (-1.9%)
XORTX Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.39% below the high.
